Clinical trials: Immunosuppressive Treatment
Hemophagocytic Lymphohistiocytosis
Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
The investigators would like to propose a pilot study evaluating the efficacy of etoposide combined with immunosuppressive agents for adult secondary hemophagocytic lymphohistiocytosis (HLH), in order to prove out whether the…
- Trial name
- HELA2012 (NCT01547143)
- Testing
- IST and/or alloHCT
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Asan Medical Center
BK Polyomavirus, Kidney Diseases
Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy
The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.
- Trial name
- NCT00104338
- Testing
- FK778
- Where
- 21 sites in United States
- Volunteers
- 45 people
- Sponsor
- Astellas Pharma Inc
Uveitis
Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy
Uveitis is an inflammatory disease of the uvea, constituting the 4th leading cause of legal blindness worldwide and the 3rd leading cause of avoidable blindness .
- Trial name
- FAIL-UVEITIS (NCT06821971)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Adherence to Medication Regime
Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant
The main objective of this study was to compare the drug compliance in patients after renal transplantation under once or twice-daily tacrolimus-based immunosuppressive regimen.
- Trial name
- NCT02251691
- Testing
- Advagraf, Prograf
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- National Taiwan University Hospital
Lupus Nephritis
Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy
Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy Resistant to Conventional Treatments
- Trial name
- RITULUP (NCT01765842)
- Testing
- Rituximab
- Where
- 3 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Liver Transplantation
Comparison of Immunosuppression Protocols After LTx in Children
Open label, randomised, prospective, onecentre Investigator Driven Study: Comparison of two protocols of immunosuppression after liver Tx in children: A: Study group - FK506-MMF.
- Trial name
- NCT00195988
- Testing
- tacrolimus, steroids, mycophenolate mofetil
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Children's Memorial Health Institute, Poland
Anemia, Aplastic, Anemia, Hypoplastic
A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
Severe aplastic anemia (SAA) is a life-threatening blood disease which can be effectively treated with immunosuppressive drug regimens or allogeneic stem cell transplantation.
- Conditions
- Anemia, Aplastic, Anemia, Hypoplastic, Thrombocytopenia
- Trial name
- NCT00922883
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sever Aplastic Anaemia, Elderly (People Aged 65 or More)
Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.
- Conditions
- Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment
- Trial name
- NCT07010237
- Testing
- Dose-attenuated IST and Hetrombopag
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Medication Adherence
Medication Adherence in Kidney Transplant Patients: SystemCHANGE™ Results of the Turkish MAGIC Randomized Clinical Trial
The SystemCHANGETM intervention harnesses patients' established daily routines/habits, environment, and important others, as possible solutions that are reoccurring and thus reliable systems that could support medication taking…
- Trial name
- NCT06106854
- Testing
- Behavioral: SystemCHANGE, Education
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Dokuz Eylul University
Aplastic Anemia
Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
Severe aplastic anemia (SAA)is characterized by the depletion of hematopoietic precursors associated with life-threatening complications.
- Trial name
- NCT01995331
- Testing
- cyclophosphamide,cyclosporine A
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiaofan Zhu
Medication Adherence, Kidney Transplantation
Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3
Medication non-adherence is a major problem in kidney transplant recipients; young people 12-24 years of age are at particularly high risk for non-adherence and graft failure compared to young children and adults.
- Trial name
- NCT04288271
- Testing
- Adherence Intervention, Healthy living education intervention
- Where
- 8 sites in United States, Canada
- Volunteers
- 96 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Myasthenia Gravis
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
To evaluate the efficacy and safety of tacrolimus capsules in patients with myasthenia gravis who are inadequately treated by glucocorticoid.
- Trial name
- NCT01325571
- Testing
- Tacrolimus capsule
- Where
- 9 sites in China
- Volunteers
- 83 people
- Sponsor
- Astellas Pharma Inc
Immunosuppresion, Thrombocytopenia
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized by pancytopenia and a hypocellular bone marrow.
- Conditions
- Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia
- Trial name
- NCT00260689
- Testing
- Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Adult Patients With Chronic Primary ITP, Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy
Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.
This study was designed as a single-center, randomized, open, two-cycle, cross-over trial. It is planned to enroll 18 healthy subjects
- Trial name
- NCT06346925
- Testing
- Herombopag Olamine Tablets
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Clostridium Difficile
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
The primary objective is to compare fidaxomicin versus vancomycin for the sustained clinical cure of Clostridium difficile Infection (CDI) in adult patients receiving immunosuppressive therapy.
- Trial name
- FREEDOM (NCT01775397)
- Testing
- Fidaxomicin, Vancomycin
- Where
- 16 sites in Austria, Denmark and 5 more
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Europe Ltd.
Primary Membranous Nephropathy
Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study
The goal of this observational study is to optimize the evaluation formula for the timing of initiating immunosuppressive therapy in primary membranous nephropathy in patients with primary membranous nephropathy.
- Trial name
- NCT06924476
- Where
- China
- Volunteers
- 282 people
- Sponsor
- Yipeng Liu
Aplastic Anaemia
HID-HSCT Versus IST as First-line Treatment for SAA
This study aims to compare the efficacy and safety of HLA-haploidentical hematopoietic stem cell transplantation (HLA-haplo HSCT) versus optimal immunosuppressive therapy (IST) as first-line treatments for severe aplastic anemia…
- Trial name
- NCT07338422
- Testing
- IST (ATG + CsA+TPORA), tranplantation
- Volunteers
- 116 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Aplastic Anemia, CSA
Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System
In this study, investigators intend to prospectively study treatment-naive AA patients (including SAA and NSAA) who are non-transplant candidates in northern China.
- Conditions
- Aplastic Anemia, CSA, Drug Therapy
- Trial name
- NCT06009965
- Testing
- CsA+ATG+Herombopag, CsA+Herombopag
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Peking Union Medical College Hospital
Nonmalignant Neoplasm
Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
RATIONALE: Immunosuppressive therapies, such as alemtuzumab and cyclosporine, may improve bone marrow function and increase blood cell counts.
- Trial name
- NCT00895739
- Testing
- alemtuzumab, cyclosporine
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Federico II University
Kidney Transplantation
An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil
This observational study will evaluate renal function in participants who underwent renal allograft transplantation and are started on combined immunosuppressive treatment containing mycophenolate mofetil (CellCept).
- Trial name
- ORANGE (NCT01672957)
- Testing
- Mycophenolate Mofetil, Immunosuppressive Therapy
- Where
- 2 sites in Hungary
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche